Filing Flows

Filing Flows › 8-K events › Bolt Biotherapeutics

Bolt Biotherapeutics: completion of an acquisition or disposition of assets

Form 8-K filed Oct 23, 2026 · items 1.01, 1.02, 2.01, 3.02, 5.02, 5.03, 7.01, 8.01

Mergers and acquisitionsBolt Biotherapeutics Announces Acquisition of Prana Therapies and $120 Million Concurrent Private Placement to Advance PRA-216 in Multiple High-Value Inflammatory Indications

What the filing says

On October 23, 2026, the Company completed its business combination with Prana. The information contained in Item 1.01 of this Current Report on Form 8-K is incorporated by reference into this Item 2.01.

ScaleThe filing names $120.0M: 6,000× Bolt Biotherapeutics' annual revenue ($20K, four times the latest quarter).

Read the filing on SEC EDGAR →

What usually followsAcross 23,525 8-Ks reporting Item 1.01 (material definitive agreement) in our universe, the stock's median move the next session was 0.0% (typical size ±1.4%, up 51% of the time); over the following 21 sessions, +1.0%. Item 1.02: 0.0% next session across 2,368. Item 2.01: +0.1% next session across 2,671. Every item ranked →

What this kind of filing means

Item 1.01 — Entry into a material definitive agreement. A material agreement is one the company considers important enough to disclose within four business days: a merger agreement, a large supply or customer contract, a credit agreement or a licence. The terms often move the company’s outlook more than a quarter’s results.

Item 1.02 — Termination of a material definitive agreement. Ending a material agreement can remove revenue, financing or a planned deal; the filing says who ended it and whether penalties apply.

Item 2.01 — Completion of an acquisition or disposition of assets. Completing an acquisition or a sale changes the company’s size and mix from this quarter on; the price paid and how it was financed are in the filing.

Item 5.02 — Departure or appointment of directors and officers. Leadership changes: who leaves, who arrives and on what terms. A sudden CEO or CFO departure without a successor deserves attention.

Bolt Biotherapeutics at a glance

Latest quarterQ2 2026
Revenue$5K
Revenue Y/Y-100%
Operating marginn/m
IndustryPharmaceutical Preparations

Bolt Biotherapeutics, Q2 2026: revenue $5K (-100% year over year). The chart follows the revenue to costs, profit and cash.

Bolt Biotherapeutics: every quarter, Q/Q and Y/Y, holders and guidance →

Other recent mergers and acquisitions

Read automatically from SEC EDGAR (13F, Form 4, Form 144, Schedule 13D/G, 8-K, XBRL), House and Senate disclosures, FINRA and exchange data; errors are possible. Not investment advice.